Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease
Authors
Keywords
GLP1-receptor agonist, Diabetes mellitus type 2, Beta-cell function, Insulin sensitivity, Meal test, Insulin clearance, Glucagon
Journal
Diabetology & Metabolic Syndrome
Volume 11, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-05-31
DOI
10.1186/s13098-019-0438-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Liraglutide use and evaluation of pancreatic outcomes in a US commercially insured population
- (2019) Donnie Funch et al. DIABETES OBESITY & METABOLISM
- Impact of the Glucagon Assay When Assessing the Effect of Chronic Liraglutide Therapy on Glucagon Secretion
- (2017) Caroline K Kramer et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes
- (2016) Nisa M. Maruthur et al. ANNALS OF INTERNAL MEDICINE
- Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study
- (2016) Preman Kumarathurai et al. Cardiovascular Diabetology
- Comparison of acarbose and metformin therapy in newly diagnosed type 2 diabetic patients with overweight and/or obesity
- (2016) Weiping Sun et al. CURRENT MEDICAL RESEARCH AND OPINION
- Newly detected abnormal glucose regulation and long-term prognosis after acute myocardial infarction: Comparison of an oral glucose tolerance test and glycosylated haemoglobin A1c
- (2016) Gokulan Pararajasingam et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review
- (2016) Amrita Ostawal et al. Diabetes Therapy
- Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review
- (2016) Amrita Ostawal et al. Diabetes Therapy
- Decreased insulin secretion and incretin concentrations and increased glucagon concentrations after a high-fat meal when compared with a high-fruit and -fiber meal
- (2015) Paresh Dandona et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial
- (2015) Kumiko Tanaka et al. CLINICAL DRUG INVESTIGATION
- Mixed meal ingestion diminishes glucose excursion in comparison with glucose ingestion via several adaptive mechanisms in people with and without type 2 diabetes
- (2015) W. Alsalim et al. DIABETES OBESITY & METABOLISM
- The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial
- (2015) Caroline K. Kramer et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Liraglutide, a Glucagon-Like Peptide-1 Analog, Increased Insulin Sensitivity Assessed by Hyperinsulinemic-Euglycemic Clamp Examination in Patients with Uncontrolled Type 2 Diabetes Mellitus
- (2015) Hideaki Jinnouchi et al. Journal of Diabetes Research
- Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?
- (2014) Nicolai J. Wewer Albrechtsen et al. DIABETOLOGIA
- Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol
- (2014) C. Anholm et al. BMJ Open
- The Canadian Diabetes Association 2013 Clinical Practice Guidelines—Raising the Bar and Setting Higher Standards!
- (2013) Alice Y.Y. Cheng et al. Canadian Journal of Diabetes
- Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study
- (2013) Sun H. Kim et al. DIABETOLOGIA
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETES CARE
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
- (2012) Juris J. Meier Nature Reviews Endocrinology
- Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity
- (2011) F. K. Knop et al. DIABETES OBESITY & METABOLISM
- Minimal model assessment of hepatic insulin extraction during an oral test from standard insulin kinetic parameters
- (2009) M. Campioni et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
- (2009) R. A. DeFronzo DIABETES
- Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
- (2009) B. Zinman et al. DIABETES CARE
- The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies
- (2009) L. Blonde et al. DIABETES OBESITY & METABOLISM
- Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
- (2009) M. Marre et al. DIABETIC MEDICINE
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- NEFA minimal model parameters estimated from the oral glucose tolerance test and the meal tolerance test
- (2008) Ray C. Boston et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
- (2008) M. Nauck et al. DIABETES CARE
- Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus
- (2008) T. Vilsbøll et al. DIABETIC MEDICINE
- Effect of Weight Loss on Liver Free Fatty Acid Uptake and Hepatic Insulin Resistance
- (2008) Antti P. M. Viljanen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started